Nuvalent’s $300M offering; Spark ends epilepsy deal; A small IPOnews2023-10-16T14:05:46+00:00October 16th, 2023|Endpoints News|
Omeros drug fails a PhIII kidney trial, stock nearly halvednews2023-10-16T13:33:27+00:00October 16th, 2023|Endpoints News|
Novo Nordisk to buy PhIII kidney disease drug from Singapore’s KBP Biosciencesnews2023-10-16T11:34:55+00:00October 16th, 2023|Endpoints News|
Jounce buyer Tang Capital offers to acquire Rain Oncology after failed bid for Ateanews2023-10-16T11:33:39+00:00October 16th, 2023|Endpoints News|
Bellerophon Therapeutics meets its end after board approves liquidationnews2023-10-16T10:55:11+00:00October 16th, 2023|Endpoints News|
Synaffix joins forces with Sotio on $740M ADC licensing deal, plans expansion after Lonza acquisitionnews2023-10-16T10:49:37+00:00October 16th, 2023|Endpoints News|
BioNTech expects up to $950M in Covid vaccine write-offs after Pfizer lowers expectationsnews2023-10-16T10:45:39+00:00October 16th, 2023|Endpoints News|
BMS buys Mirati for $4.8B; Pfizer to slash cost; Q&A with Vertex CSO; Alnylam’s Onpattro setback; and morenews2023-10-14T10:00:42+00:00October 14th, 2023|Endpoints News|
Pfizer plans $3.5B in cost cuts as sales of Covid products continue to slidenews2023-10-13T21:35:41+00:00October 13th, 2023|Endpoints News|
Pfizer’s Elrexfio, Astellas’ Veozah among new drugs recommended for authorization by European regulatory committeenews2023-10-13T19:02:13+00:00October 13th, 2023|Endpoints News|
